au.\*:("SYLVESTER R")
Results 1 to 25 of 171
Selection :
The Problem of Unity in The Praise of FollySYLVESTER R.English Literary Renaissance. 1976, Vol 6, Num 2, pp 125-139Article
PLEASURES: HIGHER AND LOWERSYLVESTER R. P.PERSONALIST (THE). 1975, Vol 56, Num 2, pp 129-137Article
More's Discussion of PerjurySYLVESTER R. S.Moreana. Bulletin Thomas More. 1977, Vol 14, Num 55-56, pp 73-77Article
Design and analysis of prostate cancer trialsSYLVESTER, R.Acta urologica belgica. 1994, Vol 62, Num 1, pp 23-29, issn 0001-7183Article
A DECISION THEORY APPROACH TO PHASE II CLINICAL TRIALS.STAQUET M; SYLVESTER R.1977; BIOMEDICINE; FR.; DA. 1977; VOL. 26; NO 4; PP. 262-266; BIBL. 8 REF.Article
Typing of human isolates of streptococcus agalactiae (group B streptococcus, GBS) strains from ZimbabweMOYO, Sylvester R; MAELAND, Johan A; BERGH, Kare et al.Journal of medical microbiology. 2002, Vol 51, Num 7, pp 595-600, issn 0022-2615Article
Antibodies raised in animals against the Streptococcus agalactiae proteins cα and R4 and normal human serum antibodies target distinct epitopesMOYO, Sylvester R; MAELAND, Johan A.Journal of medical microbiology. 2003, Vol 52, Num 5, pp 379-383, issn 0022-2615, 5 p.Article
More's Discussion of PerjurySYLVESTER, R. S.Moreana. Bulletin Thomas More Angers. 1977, Vol 14, Num 55-56, pp 73-77Article
A Bayesian approach to the design of phase II clinical trialsSYLVESTER, R. J.Biometrics. 1988, Vol 44, Num 3, pp 823-836, issn 0006-341X, 14 p.Article
GUIDELINES FOR THE PREPARATION OF E.O.R.T.C. CANCER CLINICAL TRIAL PROTOCOLSSTAQUET M; SYLVESTER R; JASMIN C et al.1980; EUROP. J. CANCER; GBR; DA. 1980; VOL. 16; NO 6; PP. 871-875; BIBL. 43 REF.Article
The putative R1 protein of Streptococcus agalactiae as serotype marker and target of protective antibodiesMOYO, Sylvester R; MAELAND, Johan A; LYNG, Randi V et al.APMIS. Acta pathologica, microbiologica et immunologica Scandinavica. 2001, Vol 109, Num 12, pp 842-848, issn 0903-4641Article
SELECTED SULFHYDRYL INHIBITORS CAPABLE OF INDUCING IMMUNITY AGAINST CANCER IN MICEKNOCK F; GALT R; OESTER Y et al.1979; ONCOLOGY; CHE; DA. 1979; VOL. 36; NO 5; PP. 197-201; BIBL. 17 REF.Article
STUDY OF CIS-DIAMMINE-DICHLORO-PLATINUM IN ADVANCED SOFT TISSUE SARCOMA. PROTOCOL 62781, MARCH 1978PINEDO HM; VENDRICK CPJ; STAQUET M et al.1978; EUROP. J. CANCER; GBR; DA. 1978; VOL. 14; NO 10; PP. 1149-1152; BIBL. 6 REF.Article
CANCER DU SEINLORIAUX C; CALLE R; PILLERON JP et al.1982; REV. MED. BRUX.; ISSN 0035-3639; BEL; DA. 1982; VOL. 3; NO 4; PP. 191-222; 30 P.; ABS. ENG; BIBL. 45 REF.Article
EVALUATION OF ADJUVANT THERAPY IN SOFT TISSUE SARCOMA: A COLLABORATIVE MULTIDISCIPLINARY APPROACHPINEDO HM; VENDRIK CPJ; BRAMWELL VHC et al.1979; EUROP. J. CANCER; GBR; DA. 1979; VOL. 15; NO 5; PP. 811-820; BIBL. 2 P.Article
PREDICTIVE ASSAYS ON INDIVIDUAL HUMAN CANCERS TO SELECT ACTIVE DRUG TREATMENTKNOCK FE; GALT RM; OESTER YT et al.1978; INDIAN J. MED. RES.; IND; DA. 1978-07; VOL. 68; PP. 107-115; BIBL. 17 REF.Article
TREATMENT OF ADVANCED SOFT TISSUE SARCOMAS WITH CHLOROZOTOCIN: A PHASE II TRIAL OF THE EORTC SOFT TISSUE AND BONE SARCOMA GROUPMOURIDSEN HT; BRAMWELL VHC; LACAVE J et al.1981; CANCER TREAT. REP.; ISSN 0361-5960; USA; DA. 1981; VOL. 65; NO 5-6; PP. 509-511; BIBL. 8 REF.Article
EORTC RANDOMIZED TRIAL FOR THE ADJUVANT THERAPY OF T1 BLADDER CARCINOMA.SCHULMAN CC; ROZENCWEIG M; STAQUET M et al.1976; EUROP. UROL.; SWITZ.; DA. 1976; VOL. 2; NO 6; PP. 271-273; BIBL. 13 REF.Article
IN VITRO ESTIMATE OF SENSITIVITY OF INDIVIDUAL HUMAN TUMORS TO ANTITUMOR AGENTS = ESTIMATION IN VITRO DE LA SENSIBILITE DES TUMEURS HUMAINES INDIVIDUELLES AUX AGENTS ANTITUMORAUXKNOCK FE; GALT RM; OESTER YT et al.1974; ONCOLOGY; SWITZ.; DA. 1974; VOL. 30; NO 1; PP. 1-22; BIBL. 1P.1/2Article
E.O.R.T.C. PROTOCOL FOR THE THERAPY OF METASTATIC SOFT TISSUE SARCOMA, A RANDOMIZED TRIAL.PINEDO MM; VENDRIK CPJ; STAQUET M et al.1977; EUROP. J. CANCER; G.B.; DA. 1977; VOL. 13; NO 7; PP. 765-771; BIBL. 9 REF.Article
INHIBITION OF DNA POLYMERASES AND NEOPLASTIC CELLS BY SELECTED SH INHIBITORSKNOCK FE; GALT RM; OESTER YT et al.1972; ONCOLOGY; SWITZ.; DA. 1972; VOL. 26; NO 6; PP. 515-528; BIBL. 1 P. 1/2Serial Issue
Eine Einführung in die statistischen Aspekte der Planung von klinischen onkologischen Studien der Phase III : Prostatakarzinom = An introduction to the statistical design of phase III cancer clinical trialsSYLVESTER, R; MINDER, C. E.Der Urologe. Ausgabe A. 1995, Vol 34, Num 5, pp 367-373, issn 0340-2592Article
INFORMATION DISSEMINATION AND OVERLOAD IN THE ALCOHOLISM TREATMENT FIELDLEVINSON D; SCHAEFER JM; SYLVESTER R et al.1982; J. STUD. ALCOHOL; ISSN 0096-882X; USA; DA. 1982; VOL. 43; NO 5; PP. 570-575; BIBL. 5 REF.Article
SENSITIVITY TESTS ON HUMAN CANCERS TO SELECT ACTIVE DRUGS FOR CLINICAL CANCER THERAPY = TESTS DE SENSIBILITE DES CANCERS HUMAINS A DES PRODUITS ACTIFS CHOISIS POUR APPLICATION THERAPEUTIQUEKNOCK FE; GALT RM; OESTER YT et al.1973; S. AFR. J. MED. SCI.; S. AFR.; DA. 1973; VOL. 38; NO 3-4; PP. 43-50; BIBL. 21 REF.Article